Enoximone

Enoximone
Clinical data
Trade names	Perfan
AHFS/Drugs.com	International Drug Names
Routes of; administration	Intravenous
ATC code	C01CE03 (WHO) ;
Legal status
Legal status	UK: POM (Prescription only);
Pharmacokinetic data
Bioavailability	50% (oral)
Protein binding	85%
Metabolism	Liver (oxidation)
Elimination half-life	4 to 10 hours
Excretion	Renal (60 to 70%)
Identifiers
	IUPAC name 4-Methyl-5-{[4-(methylsulfanyl)phenyl]carbonyl}-2,3-dihydro-1H-imidazol-2-one;
CAS Number	77671-31-9 ;
PubChem CID	53708;
DrugBank	DB04880 ;
ChemSpider	48492 ;
UNII	C7Z4ITI7L7;
KEGG	D04004 ;
ChEMBL	ChEMBL249856 ;
CompTox Dashboard (EPA)	DTXSID8045147 ;
Chemical and physical data
Formula	C12H12N2O2S
Molar mass	248.30 g·mol−1
3D model (JSmol)	Interactive image;
Melting point	255 to 258 °C (491 to 496 °F) (decomposes)
	SMILES O=C(/C1=C(/NC(=O)N1)C)c2ccc(SC)cc2;
	InChI InChI=1S/C12H12N2O2S/c1-7-10(14-12(16)13-7)11(15)8-3-5-9(17-2)6-4-8/h3-6H,1-2H3,(H2,13,14,16) ; Key:ZJKNESGOIKRXQY-UHFFFAOYSA-N ;
	(verify)

Enoximone (INN, trade name Perfan) is an imidazole phosphodiesterase inhibitor. It is used in the treatment of congestive heart failure and is selective for phosphodiesterase 3.^[1]

References

^ Boldt J, Suttner S (September 2007). "Combined use of ultra-short acting beta-blocker esmolol and intravenous phosphodiesterase 3 inhibitor enoximone". Expert Opin Pharmacother. 8 (13): 2135–47. doi:10.1517/14656566.8.13.2135. PMID 17714066. S2CID 46021219.

This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.